Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

Stopped early · Early Phase 1

Conditions studied: Pancreatic Ductal Adenocarcinoma

In brief

The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers at the University of Virginia have identified a biomarker for pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other, non-cancerous conditions involving the pancreas. These researchers have also developed PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer cells in humans.

Key facts

Study ID

NCT01962909

Run by

University of Virginia

People needed

3

Starts

2013-11-01

Expected to finish

2016-01-01

Last updated by the study team

2016-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• subject is undergoing resection of pancreas for pancreatic ductal adenocarcinoma (PDAC)
• subject must have adequate renal function
• ECOG performance status of 0-2
• women of child-bearing age and men must agree to use contraception prior to and during the study

You may not qualify if…

• subjects receiving any other investigational agents
• significant history of uncontrolled cardiac disease or central nervous system (CNS) disease
• pregnant or breastfeeding women

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.